Stay updated with breaking news from Entrypoint Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Barclays from $100.00 to $95.00 in a report issued on Thursday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $94.00 […]
Williams-Sonoma (NYSE:WSM – Free Report) had its price objective upped by Royal Bank of Canada from $295.00 to $300.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the specialty retailer’s stock. Other equities research analysts have also issued reports about the stock. Oppenheimer reissued a market perform […]
Telsey Advisory Group reissued their outperform rating on shares of Williams-Sonoma (NYSE:WSM – Free Report) in a research note published on Wednesday morning, Benzinga reports. They currently have a $340.00 price objective on the specialty retailer’s stock. Telsey Advisory Group also issued estimates for Williams-Sonoma’s Q2 2025 earnings at $3.18 EPS, Q2 2025 earnings at […]
Allient (NASDAQ:ALNT – Free Report) had its price objective cut by Roth Mkm from $42.00 to $39.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, Northland Securities reaffirmed a market perform rating and set a $40.00 price target (down previously from $45.00) on shares […]